2017 ASPIRE Grants Program

The ASPIRE Program demonstrates Pfizer’s commitment to supporting promising young investigators with an interest in advancing knowledge in defined disease areas of endocrinology.

2017 Global ASPIRE Young Investigator Research Awards in Endocrinology

DEADLINE: 2 June 2017 

Advancing the medical knowledge of the fundamental mechanisms of disease, mechanisms of action of current and potential future treatments, and to improve the care of patients with endocrine disorders.

Pfizer invites junior investigators to apply for the 2017 Global ASPIRE Young Investigator Research Awards in Endocrinology. Funding will be provided to research proposals that seek to explore translational or clinical research in the area of endocrine disease in children and young adults to address:

• Morbidity and mortality in Adult Growth Hormone Deficiency or Acromegaly
• Impact and/or needs of the patient with Growth Disorders during the pediatric and transitional years/young adult life
• Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat acromegaly or Adult Growth Hormone Deficiency.
• Early diagnosis and treatment of Adult Growth Hormone Deficiency or Acromegaly

Available Awards:

• 5 awards of up to $50,000 USD each for one year to conduct basic science, translational or clinical research generating data that will help advance the science of endocrine diseases in children and young adults.

2017 Regional ASPIRE competitive research grants programme in Endocrinology

DEADLINE: 23 June 2017

Supporting translational and clinical research through a competitive grants programme that advances medical knowledge of the fundamental mechanisms of disease and action of current and potential future treatments, and to improve the care of patients with endocrine disorders.

Pfizer invites interested investigators in Europe, Australia and New Zealand to apply for the 2017 regional ASPIRE competitive research grants programme in Endocrinology. Proposals that seek to explore translational or clinical research in the following areas of focus will be considered:

• Detection and treatment of adult growth hormone (GH) deficiency
• Earlier identification and improved management of short stature in children
• Adherence to GH therapy for both adult and paediatric patients
• Individualised GH treatment
• Identification and management of uncontrolled acromegaly

Available Awards:

• There are a total of four, €50,000 awards available. Project duration should be no more than 12 months.

 Please note that Pfizer cannot provide drug supply or funding to purchase Pfizer drug as part of this competitive research grant programme